Treatment of Pain with Oral Dosage Forms Comprising Zoledronic Acid and An Enhancer
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating or preventing pain. Typically, a pharmaceutical composition having a therapeutically effective amount of the zoledronic acid is administered to a mammal suffering from pain. The pharmaceutical composition may further comprise an enhancer, which can be a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and can have a carbon chain length of from about 4 to about 20 carbon atoms.
Claims22
A method of treating or preventing pain caused by a medical condition in a subject, the method comprising:
- administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of zoledronic acid or a salt thereof;
- wherein the pharmaceutical composition further comprises an enhancer selected from the group consisting of a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid.
A method of treating pain, comprising administering a pharmaceutical composition for oral administration to a mammal in need thereof, wherein the pharmaceutical composition is effective in delivering therapeutically effective amounts of a drug and an enhancer to an intestine, said composition comprising zoledronic acid and an enhancer, wherein the composition is in a dosage form comprising about 1 mg to about 25 mg zoledronic acid, and wherein the enhancer is a medium chain fatty acid or a salt of a medium chain fatty acid having a carbon chain length of from 6 to 20 carbon atoms, is solid at room temperature, and is the only enhancer present in the composition.
A method of treating pain, comprising administering solid oral dosage form to a mammal in need thereof, wherein the solid oral dosage form is effective in delivering therapeutically effective amounts of zoledronic acid and an enhancer to an intestine, said composition comprising zoledronic acid and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt of a medium chain fatty acid having a carbon chain length of from 6 to 20 carbon atoms, is solid at room temperature, and is the only enhancer present in the composition, and wherein upon oral delivery of the composition to a human subject.
Dependencies are inferred from the claim text.